Browsing Centre for Experimental Medicine and Rheumatology (EMR) by Author "Taylor, PC"
Now showing items 1-10 of 10
-
Corrigendum: The RA-MAP Consortium: a working model for academia-industry collaboration.
Cope, AP; Barnes, MR; Belson, A; Binks, M; Brockbank, S; Bonachela-Capdevila, F; Carini, C; Fisher, BA; Goodyear, CS; Emery, P (2018-01-24)This corrects the article DOI: 10.1038/nrrheum.2017.200. -
Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes
Lewis, MJ; Barnes, MR; Blighe, K; Goldmann, K; Rana, S; Hackney, JA; Ramamoorthi, N; John, CR; Watson, DS; Kummerfeld, SK (2019-08-27) -
O07 Randomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy
Humby, FC; Lewis, M; Durez, P; Buch, MH; Bombardieri, M; Rizvi, H; Rivellese, F; Fossati, L; Hands, R; Giorli, G (2020-04-01) -
The RA-MAP Consortium: a working model for academia-industry collaboration
Cope, AP; Barnes, MR; Belson, A; Binks, M; Brockbank, S; Bonachela-Capdevila, F; Carini, C; Fisher, BA; Goodyear, CS; Emery, P (2018-01) -
RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients
Isaacs, JD; Brockbank, S; Pedersen, AW; Hilkens, C; Anderson, A; Stocks, P; Lendrem, D; Tarn, J; Smith, GR; Allen, B (2022) -
RANDOMISED, OPEN LABELLED CLINICAL TRIAL TO INVESTIGATE SYNOVIAL MECHANISMS DETERMINING RESPONSE: RESISTANCE TO RITUXIMAB VERSUS TOCILIZUMAB IN RA PATIENTS FAILING TNF INHIBITOR THERAPY
Humby, FC; Lewis, M; Durez, P; Buch, MH; Bombardieri, M; Rizvi, H; Rivellese, F; Fossati, L; Hands, R; Giorli, G (2020-04) -
Rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients: the R4-RA RCT
Humby, F; Durez, P; Buch, MH; Lewis, MJ; Bombardieri, M; John, C; Rizvi, H; Warren, L; Peel, J; Fossati-Jimack, L (2022)<h4>Background</h4>Although biological therapies have transformed the outlook for those with rheumatoid arthritis, there is a lack of any meaningful response in approximately 40% of patients. The role of B cells in rheumatoid ... -
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Humby, F; Durez, P; Buch, MH; Lewis, MJ; Rizvi, H; Rivellese, F; Nerviani, A; Giorli, G; Mahto, A; Montecucco, C (2021-01-23)BACKGROUND: Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is mechanistically still unexplained. Because more ... -
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials
Rivellese, F; Nerviani, A; Giorli, G; Warren, L; Jaworska, E; Bombardieri, M; Lewis, MJ; Humby, F; Pratt, AG; Filer, A (2023-11-01)Background: Despite highly effective targeted therapies for rheumatoid arthritis, about 40% of patients respond poorly, and predictive biomarkers for treatment choices are lacking. We did a biopsy-driven trial to compare ... -
Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC)
Lliso-Ribera, G; Humby, F; Lewis, M; Nerviani, A; Mauro, D; Rivellese, F; Kelly, S; Hands, R; Bene, F; Ramamoorthi, N (2019-12)